lysergic acid diethylamide Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central MeSH PubChem

Active Ingredient History

NOW
  • Now
Lysergic acid diethylamide, commonly known as LSD, and known colloquially as acid or lucy, is a potent psychedelic drug. Effects typically include intensified thoughts, emotions, and sensory perception. At sufficiently high dosages, LSD manifests primarily mental, visual, and auditory hallucinations. Dilated pupils, increased blood pressure, and increased body temperature are typical.   Wikipedia

Chemistry

  • SMILES: CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34
  • InChIKey: VAYOSLLFUXYJDT-RDTXWAMCSA-N
  • Mol. Mass: 323.44
  • ALogP: 2.91
  • ChEMBL Molecule:
    lysergide  
More Chemistry

Pharmacology

Alternative names

9,10-didehydro-6-methylergoline-8 beta-carboxamide | 9,10-didehydro-n,n-diethyl-6-methylergoline-8b-carboxamide | delysid | dextrolysergic acid diethylamide | diethylamid kyseliny lysergove | d-lsd | d-lsd-25 | d-lysergic acid amide | d-lysergic acid dethylamide | d-lysergic acid diethylamide | d-lysergic acid n,n-diethylamide | lsd | (+)-lsd | lsd-25 | lysergamid | lysergamide | lysergaure diethylamid | lysergic acid amide | (+)-lysergic acid diethylamide | lysergic acid diethylamide | lysergic acid diethylamide-25 | lysergide | lysergidum | n,n-diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide | n,n-diethyl-d-lysergamide | n,n-diethyllysergamide | n,n-diethyl-(+)-lysergamide

Organizations (24)

Research & Development (24)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (26)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (26)


 

Alcohol-Induced Disorders (Phase 2)

Altruism (Phase 1/Phase 2)

Anxiety (Phase 2)

Anxiety Disorders (Phase 2)

Caregiver Burden (Phase 2)

Cluster Headache (Phase 2)

Demoralization (Phase 2)

Depression (Phase 2)

Depressive Disorder, Major (Phase 2)

Healthy Volunteers (Phase 1)

Hodgkin Disease (Phase 3)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Myeloproliferative Disorders (Phase 2)

Neoplasms (Phase 2)

Pain (Phase 2)

Palliative Care (Phase 2)

Patients (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Primary Myelofibrosis (Phase 2)

Psychological Distress (Phase 2)

Quality of Life (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 37
  • # of Trial Organizations: 24

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue